These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31386865)

  • 81. Dexlansoprazole and Esomeprazole Do Not Affect Bone Homeostasis in Healthy Postmenopausal Women.
    Hansen KE; Nieves JW; Nudurupati S; Metz DC; Perez MC
    Gastroenterology; 2019 Mar; 156(4):926-934.e6. PubMed ID: 30445008
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg.
    Kukulka M; Eisenberg C; Nudurupati S
    Clin Exp Gastroenterol; 2011; 4():213-20. PubMed ID: 22016582
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Enantioselective determination of (R)- and (S)-lansoprazole in human plasma by chiral liquid chromatography with mass spectrometry and its application to a stereoselective pharmacokinetic study.
    Sun L; Cao Y; Jiao H; Fang Y; Yang Z; Bian M; Zhang H; Gong X; Wang Y
    J Sep Sci; 2015 Nov; 38(21):3696-703. PubMed ID: 26333119
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Pediatric drug formulation of sodium benzoate extended-release granules.
    Combescot E; Morat G; de Lonlay P; Boudy V
    Pharm Dev Technol; 2016; 21(3):261-7. PubMed ID: 25582668
    [TBL] [Abstract][Full Text] [Related]  

  • 85. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
    Welage LS; Berardi RR
    J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study.
    Han S; Choi HY; Kim YH; Choi S; Kim S; Nam JY; Kim B; Song GS; Lim HS; Bae KS
    Gut Liver; 2023 Jan; 17(1):92-99. PubMed ID: 36317518
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease.
    Kukulka M; Nudurupati S; Perez MC
    Clin Exp Gastroenterol; 2014; 7():461-71. PubMed ID: 25525378
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Formulation of Dosage Forms with Proton Pump Inhibitors: State of the Art, Challenges and Future Perspectives.
    Srebro J; Brniak W; Mendyk A
    Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297478
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Understanding biorelevant drug release from a novel thermoplastic capsule by considering microstructural formulation changes during hydration.
    Misic Z; Urbani R; Pfohl T; Muffler K; Sydow G; Kuentz M
    Pharm Res; 2014 Jan; 31(1):194-203. PubMed ID: 23921490
    [TBL] [Abstract][Full Text] [Related]  

  • 91. A developed composite hard-gelatin capsules: delayed-release enteric properties.
    Nezhad Mohseni M; Najafpour Darzi G; Ramezani R; Jahani A
    Heliyon; 2022 Dec; 8(12):e12265. PubMed ID: 36619422
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Prolonged gastric stasis of enteric-coated granules.
    Matsukawa Y; Hayashi I
    BMJ Case Rep; 2009; 2009():bcr0820080622. PubMed ID: 21687043
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Input Estimation for Extended-Release Formulations Exemplified with Exenatide.
    Trägårdh M; Chappell MJ; Palm JE; Evans ND; Janzén DLI; Gennemark P
    Front Bioeng Biotechnol; 2017; 5():24. PubMed ID: 28470000
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Greenness-sustainability metrics for assessment smart-chemometric spectrophotometric strategy for evaluation of the combination of six gastric proton-pump inhibitors with two selected impurities.
    Amin KFM
    MethodsX; 2024 Jun; 12():102670. PubMed ID: 38577411
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The Effect of Dexlansoprazole on Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
    Nunes GP; Silveira TC; Marciano JVS; Dos Reis-Prado AH; Ferrisse TM; Dos Anjos EB; Fernandes MH
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279248
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Expanding the Use of Peroxygenase from Oat Flour in Organic Synthesis: Enantioselective Oxidation of Sulfides.
    Sanfilippo C; Cernuto F; Patti A
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108626
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Pharmacokinetics and Pharmacodynamics of Esomezol DR, a New Dual Delayed-Release Formulation of Esomeprazole 20 Mg or 40 Mg, in Healthy Subjects.
    Kim HC; Yang E; Ban MS; Kim YK; Hong SH; Jung J; Jang IJ; Lee S
    Drug Des Devel Ther; 2023; 17():1115-1124. PubMed ID: 37077412
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Pharmaceutical Coating and Its Different Approaches, a Review.
    Salawi A
    Polymers (Basel); 2022 Aug; 14(16):. PubMed ID: 36015575
    [TBL] [Abstract][Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.